Who are the top shareholders of the Senores Pharma.?

The top shareholders of Senores Pharma include promoter Swapnil Jatin Shah with 7.72%, Aditya Birla Sun Life Insurance Company Limited at 3.71%, mutual funds with 3.23%, foreign institutional investors holding 4.17%, and individual investors collectively owning 31.43%.

The top shareholders of Senores Pharma include the promoters, who are the majority shareholders. The promoter with the highest holding is Swapnil Jatin Shah, owning 7.72% of the company. Additionally, Aditya Birla Sun Life Insurance Company Limited is the highest public shareholder, holding 3.71%. The company also has mutual funds holding 3.23% across five schemes and foreign institutional investors (FIIs) holding 4.17% through 21 different entities. Individual investors collectively hold 31.43% of the shares.

What does Senores Pharma. do?

Senores Pharmaceuticals Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 114 Cr and a net profit of 18 Cr for March 2025. It was incorporated in 2017 and became a public company in 2023.

Overview: <BR>Senores Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History: <BR>Senores Pharmaceuticals Ltd was originally incorporated as "Senores Pharmaceuticals Private Limited" in 2017. The company transitioned to a Public Limited Company and changed its name to "Senores Pharmaceuticals Limited" in 2023. The most recent quarterly results reported net sales and net profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 114 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 18 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 2,453 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 41.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.09 <BR>Return on Equity: 7.45% <BR>Price to Book: 3.09 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Has Senores Pharma. declared dividend?

No Dividend History Available

What is the technical trend for Senores Pharma.?

As of March 10, 2025, Senores Pharma's technical trend is neutral with no strong signals, as indicators like MACD and RSI show a sideways movement, despite recent outperformance against the Sensex.

As of 10 March 2025, the technical trend for Senores Pharma has changed to sideways. The current technical stance is neutral, with no strong bullish or bearish signals evident. The MACD, RSI, and other indicators do not provide clear directionality on the weekly or monthly time frames. The Dow Theory indicates no trend on the weekly and monthly levels, and the On-Balance Volume (OBV) also shows no trend. The stock's recent performance has outpaced the Sensex over the past week and month, but the year-to-date return is negative, suggesting mixed sentiment. Overall, the lack of definitive indicators keeps the outlook neutral.

Who are the peers of the Senores Pharma.?

Senores Pharma's peers include Gufic BioScience, Advanced Enzyme, Morepen Labs, Indoco Remedies, IOL Chemicals, Panacea Biotec, Novartis India, Solara Active, SMS Pharma, and Zota Health Care. Management risk varies from excellent at Gufic BioScience and Advanced Enzyme to below average at Senores Pharma, with growth rated as excellent for Senores Pharma and average for most others.

Peers: The peers of Senores Pharma. are Gufic BioScience, Advanced Enzyme, Morepen Labs., Indoco Remedies, IOL Chemicals, Panacea Biotec, Novartis India, Solara Active, SMS Pharma, and Zota Health Care.<BR><BR>Quality Snapshot: Excellent management risk is observed at Gufic BioScience and Advanced Enzyme, while Average management risk is found at Morepen Labs., Indoco Remedies, IOL Chemicals, Novartis India, SMS Pharma., and the rest. Below Average management risk is noted at Senores Pharma., Panacea Biotec, and Solara Active. Growth is Excellent at Senores Pharma., Good at Morepen Labs. and Novartis India, while Average growth is seen at Indoco Remedies, and the rest. Below Average growth is recorded at Advanced Enzyme, IOL Chemicals, Panacea Biotec, Solara Active, and Zota Health Care. Capital Structure is Excellent at Gufic BioScience, Advanced Enzyme, IOL Chemicals, and Novartis India, while Good capital structure is noted at Senores Pharma., Average at Indoco Remedies and SMS Pharma., and Below Average at Panacea Biotec and Solara Active.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Panacea Biotec at 215.30%, while the lowest is Advanced Enzyme at -12.83%. Senores Pharma.'s 1-year return is not available for comparison. Additionally, peers with negative six-month returns include Gufic BioScience and Advanced Enzyme.

How big is Senores Pharma.?

As of 24th July, Senores Pharmaceuticals Ltd has a market capitalization of 2,975.00 Cr, with recent net sales of 435.61 Cr and a net profit of 65.47 Cr. The company's shareholder's funds are 204.27 Cr, and total assets amount to 606.92 Cr.

As of 24th July, Senores Pharmaceuticals Ltd has a market capitalization of 2,975.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Senores Pharmaceuticals reported Net Sales of 435.61 Cr and a Net Profit of 65.47 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 204.27 Cr and Total Assets of 606.92 Cr.

Is Senores Pharma. overvalued or undervalued?

As of September 18, 2025, Senores Pharma is considered very expensive and overvalued with a PE ratio of 56.49 and lower returns compared to peers, despite a year-to-date stock performance of 25.84% against the Sensex's 6.24%.

As of 18 September 2025, the valuation grade for Senores Pharma has moved from expensive to very expensive, indicating a significant shift in its market perception. The company is currently deemed overvalued, with a PE ratio of 56.49, an EV to EBIT of 44.43, and an EV to EBITDA of 36.09. These ratios are considerably higher than its peers, such as Sun Pharma, which has a PE ratio of 34.46 and an EV to EBITDA of 23.34, and Cipla, which boasts a more attractive PE ratio of 23.65 and an EV to EBITDA of 16.67.<BR><BR>In comparison to its industry, Senores Pharma's financial metrics suggest that it is not only overvalued but also lacks competitive returns, as evidenced by its ROE of 7.45% and ROCE of 10.18%. While the stock has outperformed the Sensex year-to-date with a return of 25.84% compared to the Sensex's 6.24%, the overall valuation metrics indicate that investors may be paying a premium that is not justified by the company's financial performance.

When is the next results date for Senores Pharma.?

Senores Pharma will announce its results on November 6, 2025.

Senores Pharma is scheduled to declare its results on November 6, 2025.

How has been the historical performance of Senores Pharma.?

Senores Pharma experienced significant growth from March 2024 to March 2025, with net sales rising from 214.52 Cr to 398.25 Cr and profit after tax increasing from 32.71 Cr to 58.34 Cr, despite higher raw material and employee costs. Total assets and liabilities both grew to 1,208.19 Cr, while cash flow from financing activities improved significantly.

Answer:<BR>The historical performance of Senores Pharma shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Senores Pharma's net sales increased substantially from 214.52 Cr in March 2024 to 398.25 Cr in March 2025, reflecting strong operational growth. Total operating income followed the same trend, rising to 398.25 Cr from 214.52 Cr. However, raw material costs surged to 91.64 Cr from 31.96 Cr, and employee costs also rose to 60.37 Cr from 35.46 Cr, contributing to a total expenditure of 308.55 Cr, up from 172.92 Cr. Operating profit (PBDIT) improved significantly to 108.96 Cr from 44.42 Cr, with profit before tax reaching 70.57 Cr compared to 24.95 Cr the previous year. Profit after tax also saw an increase to 58.34 Cr from 32.71 Cr. The company's total assets grew to 1,208.19 Cr from 606.92 Cr, while total liabilities increased to 1,208.19 Cr from 606.92 Cr as well. Cash flow from operating activities remained negative at -45.00 Cr, but cash flow from financing activities turned positive at 573.00 Cr, leading to a net cash inflow of 97.00 Cr, up from 7.00 Cr. Overall, Senores Pharma demonstrated robust growth in revenue and profitability, alongside increased asset and liability levels.

Are Senores Pharma. latest results good or bad?

Senores Pharmaceuticals reported strong quarterly results, with net sales increasing by 60.75% year-on-year and net profit rising by 152.18%. While the operational performance is impressive, the stock's high valuation at 60 times trailing earnings may raise concerns about the sustainability of this growth.

Senores Pharmaceuticals has reported impressive results for the latest quarter, indicating strong operational performance. The company achieved net sales of ₹161.76 crores, marking a significant year-on-year growth of 60.75% and a sequential increase of 17.23%. This growth is complemented by a substantial expansion in operating margins, which rose to 32.28% from 23.68% in the same quarter last year, showcasing improved operational efficiency.<BR><BR>Additionally, the net profit for the quarter reached ₹32.38 crores, reflecting a remarkable increase of 152.18% year-on-year and 64.12% quarter-on-quarter. The profit after tax margin also improved to 19.64%, up from 13.30% in the previous year.<BR><BR>Overall, the results can be considered very positive, highlighting the company's robust growth trajectory and operational excellence. However, it's important to note that the stock is currently trading at a high valuation of 60 times trailing earnings, which raises questions about the sustainability of this growth at such elevated price levels. Investors should weigh the strong performance against the premium valuation when considering the company's future prospects.

Should I buy, sell or hold Senores Pharma.?

Which are the latest news on Senores Pharma.?

Why is Senores Pharma. falling/rising?

As of 03-Dec, Senores Pharmaceuticals Ltd's stock price is at 784.45, down 0.98%, due to a three-day decline and reduced investor participation. Despite strong long-term growth indicators, negative short-term market sentiment is impacting the stock's performance.

As of 03-Dec, Senores Pharmaceuticals Ltd's stock price is falling, currently at 784.45, which reflects a decrease of 7.75 or 0.98%. This decline can be attributed to several factors. The stock has underperformed its sector by 0.97% today and has been on a consecutive fall for the last three days, resulting in a total drop of 4.75% during this period. Additionally, there has been a significant decrease in investor participation, with the delivery volume on December 2 falling by 52.42% compared to the five-day average. <BR><BR>Despite the company's strong long-term growth indicators, such as a net sales growth rate of 85.60% and an operating profit growth of 130.72%, the recent performance has not translated into positive short-term stock movements. The stock's moving averages indicate that it is currently lower than the 5-day and 20-day moving averages, which may also contribute to the downward pressure on the stock price. Overall, while the company has shown healthy financial results in recent quarters, the immediate market sentiment appears to be negative, leading to the current decline in stock price.